
Drug Development Pharma - February 12, 2014
AstraZeneca’s Onglyza on review
The diabetes drug Onglyza is under the FDA’s microscope as the agency said it would review possible heart risks associated with the medication. The decision comes after a study published in the New England Journal of Medicine. The study flagged an increase in heart failure hospitalizations among patients who used Onglyza (saxagliptin). The active ingredient is […]